Biogen Inc.

As of June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs carries a market capitalization of 153.89B, placing it among publicly traded companies globally. Its enterprise value stands at 190.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs has 924.76M shares outstanding.

As of June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs trades at a trailing price-to-earnings ratio of 35.51. The price-to-sales ratio is 2.96, and the price-to-book ratio stands at 1.58.

As of June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs trades at an EV/EBITDA multiple of 19.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.67 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs trades at an EV/FCF ratio of 13.52, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 190.43B versus a market cap of 153.89B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 44.33, indicating elevated leverage, while an interest coverage ratio of 6.80 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs posted a return on equity (ROE) of 4.58, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.50 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.16, useful for judging operating efficiency across full business cycles. The company generates approximately 6.89M in revenue per employee across its workforce of 7,526.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.12 indicates how many times Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs recorded 913.88M in income tax expense. That works out to an effective tax rate of 17.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.23B, leaving 4.31B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 14, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs's stock has gained approximately 43.58% over the past 52 weeks. The 50-day moving average sits at 167.18, while the 200-day moving average is 144.91.

Over the twelve months ended June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs generated 51.83B in revenue and converted that into 4.31B in net income, yielding earnings per share of 4.66. EBITDA reached 10.01B, while operating income came in at 10.00B.

As of June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs holds 6.64B in cash and equivalents against 43.19B in total debt, resulting in a net debt position of 35.18B. Total book value stands at 97.43B, with working capital of 17.52B providing operational flexibility.

Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs produced 14.88B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.01B in capital expenditures, free cash flow totaled 12.87B - equivalent to 13.98 per share.

Over the twelve months ended June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs posted a gross margin of 73.99, reflecting its pricing power and cost economics. The operating margin of 19.29 and net profit margin of 8.32 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 8.36, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -3.31, meaning Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Biogen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 1/6 Shs has an Altman Z-Score of 5.65, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.